STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

Staar Surgical reported a net loss of $18.3 million and a 46.4% decline to -$0.37 in diluted earnings per share for the quarter.

Staar Surgical reported a $80.4M full-year loss and 23.7% revenue decline, with analysts maintaining hold ratings as the ...

Staar Surgical (Nasdaq:STAA) announced that it received FDA approval for an expanded age indication for its Evo lenses.

The U.S. Food and Drug Administration (FDA) on Tuesday approved an expanded age indication for Staar Surgical Company’s STAA ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, ...

GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)-- Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: ...

Deferring to Alcon to Solicit Proxies for the Proposed Merger Will Not Relieve STAAR’s Board of Its Credibility Deficit with Shareholders HONG KONG--(BUSINESS WIRE)-- Yunqi Capital Limited (together ...

The expanded age indication is supported by results from a 3-year FDA clinical trial that included 629 eyes. The EVO ICL demonstrated “a strong safety profile” with no reported cases of pupillary ...